Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm (Nasdaq: KPTI) entered a private placement with RA Capital expected to raise approximately $30 million in gross proceeds, with an additional $44 million/b) if accompanying warrants are exercised in full. The financing includes 1,030,354 common shares, 3,391,164 pre-funded warrants, and warrants for 4,421,518 shares.The offering was priced at-the-market under Nasdaq rules and is expected to close on or about March 26, 2026. Net proceeds plus existing liquidity are expected to fund operations into late Q3 2026. Proceeds are for general corporate purposes and planned clinical trial activities.
Karyopharm (Nasdaq: KPTI) reported topline Phase 3 SENTRY results in frontline myelofibrosis (n=353). The trial met its first co-primary endpoint: SVR35 50% vs 28% at Week 24 (one-sided p<0.0001) for selinexor plus ruxolitinib. The Abs-TSS symptom endpoint was not met. A promising overall survival signal (HR 0.43) was observed; safety showed higher grade 3+ TEAEs with the combination.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,450 restricted stock units (RSUs) to two newly hired employees, effective Feb 28, 2026, under its 2022 Inducement Stock Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Each RSU vests over three years with 33 1/3% vesting on each consecutive anniversary and is contingent on continued service through each vesting date.
Karyopharm (Nasdaq: KPTI) reported full‑year 2025 total revenue of $146.1M and U.S. XPOVIO net product revenue of $114.9M. The company reiterated 2026 guidance of $130M–$150M total revenue and $115M–$130M U.S. XPOVIO revenue.
Key clinical catalysts include Phase 3 SENTRY top‑line data expected in March 2026 and Phase 3 XPORT‑EC‑042 data expected in mid‑2026. Cash and financing items drove a $196.0M net loss for 2025 and a cash balance of $64.1M at year‑end.
Karyopharm (Nasdaq: KPTI) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates.
Dial-in numbers are provided for domestic and international callers, and accompanying slides plus an archived webcast will be available on the company’s Investor "Events & Presentations" webpage about two hours after the call.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,799 restricted stock units (RSUs) to four newly hired employees, effective January 31, 2026, under its 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).
Each RSU vests over three years with 33 1/3% vesting on each anniversary, conditioned on continued service through each vesting date.
Karyopharm (Nasdaq: KPTI) provided preliminary unaudited revenue estimates for 2025 and outlined 2026 objectives, including two near‑term Phase 3 data readouts. The company expects full‑year 2025 total revenue ≈ $145M and U.S. XPOVIO net product revenue ≈ $115M. Top‑line SENTRY myelofibrosis data are expected in March 2026 and top‑line XPORT‑EC‑042 endometrial cancer data are expected in mid‑2026. Cash, cash equivalents, restricted cash and investments were ≈ $64M as of December 31, 2025, with liquidity expected to fund operations into the second quarter of 2026. The company completed SENTRY enrollment (353 patients) and completed strategic financings to extend runway.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,533 restricted stock units (RSUs) to two newly hired employees, with a Grant Date of December 31, 2025. The awards were made under the company's 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).
Each RSU vests over three years, with 33 1/3% of the shares vesting on each consecutive anniversary of the Grant Date, subject to the recipient's continued service through each vesting date.
Karyopharm (Nasdaq: KPTI) announced that its senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET.
Dr. Harrison is Professor of Myeloproliferative Neoplasms and Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and is described as a leading international expert in myelofibrosis. A live webcast will be available under the company's Investor "Events & Presentations" page and will be posted for replay after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) granted inducement awards to seven newly hired employees as of November 30, 2025 under its 2022 Inducement Stock Incentive Plan.
The company issued stock options to purchase an aggregate of 2,800 shares at an exercise price of $5.62 (closing price on the Grant Date) and granted an aggregate of 15,791 restricted stock units (RSUs). Options vest over four years (25% after one year, then monthly 1/48th), and RSUs vest over three years (33 1/3% each year), each subject to continued service.